Zydus Lifesciences received an Establishment Inspection Report from the US FDA for its injectable manufacturing plant in Ahmedabad. The report gave a Voluntary Action Indicated classification. The inspection took place between 27 April and 5 May 2026.
Investors are watching the company’s share price closely as it will be reported on 3 August. The board is scheduled to meet on 11 August to review and approve the unaudited financial results for the quarter ended 30 June 2026.
The company also announced that it has received approval to start a Phase III clinical trial of Desidustat. The trial will test the drug for anemia in sickle cell disease patients. It is being carried out in partnership with the Indian Council of Medical Research.
The stock closed at ₹1,126.50 in the previous session, up ₹11.00 or 0.99 percent. The shares have reached a 52‑week high of ₹1,181 and a low of ₹835.85. Currently it trades 4.61 percent below its high and 34.77 percent above its low.
The company’s market capitalisation stands at ₹113,352.26 crore. This reflects the overall market value of the firm.
Overall, the company’s regulatory updates and upcoming board meeting are key factors that could influence the stock’s performance in the near term.